Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it
The model's full reasoning — Q4 2022 call → NOWe need to answer YES or NO based on the transcript. The question asks: Does management describe ONE identifiable offering or initiative that is still a smaller part of overall results, for which BOTH (1) customer response is running ahead of what company prepared for, and (2) company is responding right now by putting more of itself behind it. We need to find an offering that is small relative to total business, with current uptake exceeding preparation, and concrete steps underway to expand. Look at the transcript. Management discusses several things: endpoint ICs, systems, reader ICs, E-family, M700, authenticity, etc. The authenticity offering (Impinj Authenticity) is mentioned. Let's see if it fits. From transcript: Jeff Dossett says: "I'm very encouraged by the growing level of interest among our solution partners and an increasing number of enterprise end customers who are guiding Impinj authenticity solution engine. Recall that it's an innovative differentiated Impinj platform solution engine that delivers cryptographic product authentication that protects brands and consumers. The pipeline is growing nicely. Of course, the time and pacing -- or the pace and timing of those opportunities is challenging to predict. But I am even more optimistic today than when we had this conversation last quarter regarding the opportunity not only to build endpoint IC recurring revenue, but also to establish a new services revenue opportunity in the longer term." Chris Diorio adds: "we're the first ones to truly launch and endpoint IC design for broad-based adoption that has a cryptographic engine and the key in it... we're excited about where we stand today. We're excited about our pipeline, and I personally I'm excited about the long-term opportunities, not just a year or two out, but further out in time as well." Later, Cary Baker says: "And Scott, unfortunately, my answer on the authentication model is going to be roughly similar. It's a little too early to model authentication revenue in 2023. We are shipping or we will ship units on our endpoint IC authentic and extreme endpoint IC some as early as Q1, but very small quantities at this stage. So it won't really hit the radar." So authenticity is a small offering, with small quantities.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).